The Effect of Asphyxia on the Pharmacokinetics of Ceftazidime in the Term Newborn

ABSTRACT: The multiple-dose pharmacokinetics of ceftazidime (CAZ) (administered twice daily in a 50 mg/kg of body weight i.v. dose) were studied in 10 severely asphyxiated term infants with suspected septicemia on d 3 of life. Nine term infants with suspected septicemia but without asphyxia served as controls. Blood samples were collected from an arterial catheter at 0, 0.5, 1, 2, 4, 8, and 12 h after an i.v. bolus injection. A high performance liquid chromatography method was used to determine CAZ concentrations from serum. CAZ pharmacokinetics followed a one-compartment open model. The GFRs of all infants were simultaneously studied by means of the 24-h continuous inulin infusion technique. Elimination serum half-life (5.86 ± 1.13 h versus 3.85 ± 0.40 h) and serum trough concentrations (46 ± 14 mg/L versus 23 ± 7 mg/L) of CAZ were significantly (p < 0.001) increased in the asphyxiated newborn, whereas total body clearance of CAZ (128.4 ± 25.1 mL/h versus 205.7 ± 55.4 mL/h), CAZ clearance per kg (40.9 ± 6.1 mL/h/kg versus 60.8 ± 8.3 mL/h/kg), and the GFR expressed in mL/min (3.14 ± 0.43 versus 4.73 ± 0.89) were significantly (p < 0.001) decreased in the asphyxiated newborn. We conclude that twice daily administration of 50 mg/kg of body weight CAZ given to asphyxiated term newborns in the first days of life results in significantly higher serum trough levels in comparison with control infants. The impaired CAZ clearance is a result of a significantly decreased GFR.

[1]  W. Hop,et al.  Effects of Prenatal Exposure to Betamethasone and Indomethacin on the Glomerular Filtration Rate in the Preterm Infant , 1994, Pediatric Research.

[2]  G. Jackson,et al.  Ceftazidime encephalopathy: absence status and toxic hallucinations. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[3]  B. Danielson,et al.  Neurotoxicity Associated with Ceftazidime Therapy in Geriatric Patients with Renal Dysfunction , 1991, Pharmacotherapy.

[4]  O. Cars,et al.  Neurotoxicity of β-lactam antibiotics: predisposing factors and pathogenesis , 1991 .

[5]  J. Parer,et al.  Effects of severe reduction in maternal placental blood flow on blood flow distribution in the sheep fetus. , 1991, Journal of developmental physiology.

[6]  D. Hendrick,et al.  Hallucinations in association with ceftazidime. , 1988, BMJ.

[7]  U. Schaad,et al.  Effects of Antimicrobial Agents Used for Therapy of CNS Infections on Dissociated Brain Cell Cultures , 1988, Pediatric Research.

[8]  C. Quandt,et al.  Ceftazidime-induced encephalopathy in a patient with renal impairment. , 1988, Archives of neurology.

[9]  L. Gentry.  Antimicrobial Activity, Pharmacokinetics, Therapeutic Indications and Adverse Reactions of Ceftazidime , 1985, Pharmacotherapy.

[10]  G. Hodges,et al.  Neurotoxicity of antibacterial agents , 1984, Annals of internal medicine.

[11]  R. Mccance,et al.  The Influence of Events during the Last Few Days in utero on Tissue Destruction and Renal Function in the First Two Days of Independent Life , 1954, Archives of disease in childhood.

[12]  O. Cars,et al.  Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. , 1991, The Journal of antimicrobial chemotherapy.

[13]  D. Höffler,et al.  Cephalosporin-induced encephalopathy in uremic patients. , 1988, Nephron.

[14]  H. Neu.  In-vitro activity of ceftazidime, a beta-lactamase stable cephalosporin. , 1981, The Journal of antimicrobial chemotherapy.

[15]  J. Ayrton.  Assay of ceftazidime in biological fluids using high-pressure liquid chromatography. , 1981, The Journal of antimicrobial chemotherapy.